- Business
- Kangmei Pharmaceutical Co., Ltd. (600518.SS) engages primarily in the research, development, production, and sale of traditional Chinese medicines, proprietary Chinese medicines, chemical preparations, health foods, and related products in China. The company operates an integrated model across the traditional Chinese medicine industry chain, with core offerings that include Chinese medicine tablets such as Ganmaoling Granule for colds and flu and Qingkailing Capsules for immune support; herbal ingredients like American ginseng, angelica, honeysuckle, notoginseng, radix codonopsis, and salvia; chemical drugs including clarithromycin, doxazosin mesylate, paracetamol and pseudoephedrine hydrochloride, and propiverine hydrochloride; as well as health foods, medical equipment, and pharmaceutical logistics services through medical institutions, smart pharmacies, OTC retail, chain drug stores, direct sales, and e-commerce channels. It maintains over 30 branches nationwide, focusing on the domestic market while pursuing international expansion into Southeast Asia, and also engages in property management and hospital operations.
Founded in 1997 by Ma Xingtian in Puning, Jieyang, Guangdong province, the company is headquartered in Shenzhen, Guangdong, with additional facilities in Puning, and listed on the Shanghai Stock Exchange in March 2001. Kangmei Pharmaceutical became actually controlled by Guangdong Shennong Enterprise Management Partnership (Limited Partnership) following the introduction of state-owned capital and industry investors in 2021 as part of its restructuring efforts after a major 2019 financial scandal involving overstated revenues, profits, and cash holdings. In recent developments, the company received CNY 6.5 billion in funding from Guangdong Shennong Enterprise Management Partnership; signed a settlement agreement in July 2025 with Guangzhou Pharmaceutical Group Co., Ltd. to resolve historical debts of RMB 43.5 million via its subsidiary Chengdu Kangmei Pharmaceutical Co., Ltd.; and continues to implement its "12355" Global Strategy, emphasizing traditional Chinese medicine tablets, smart pharmacies, and big health industry expansion. As of 2025, Kangmei reports ongoing operational activities, including Q3 performance briefings and semi-annual results announcements, amid efforts to stabilize post-restructuring with total assets previously valued at around CNY 47.2 billion.